2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

506. Bone Marrow Microenvironment

Program: Oral Abstract Session
Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 295-296
Technology and Procedures, Assays, Imaging, Omics Technologies, Cell Expansion, Biological Processes, CHIP, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Embryo/Fetus, Animal Model
PAPER

205 Megakaryocytic niche regulates clonal hematopoiesis of indeterminate potential and associated cardiovascular disease

Sen Zhang, PhD, Maura Lima Pereira Bueno, PhD2, Chandani M Patel, MS3, Eva Hin Wa Leung, MS4, Zhe Yu, PhD5, Jordan Jousma, PhD6, Gege Yan, PhD7, Sang-Ging Ong, PhD8, Constantinos Chronis, PhD9, Sandra Pinho, PhD10
1 University of Illinois Chicago, Chicago, Illinois, United States
2 University of Illinois Chicago, Chicago, Illinois, United States
3 University of Illinois Chicago, Chicago, Illinois, United States
4 University of Illinois Chicago, Chicago, Illinois, United States
5 University of California San Diego, San Diego, California, United States
6 University of Illinois Chicago, Chicago, Illinois, United States
7 University of Illinois Chicago, Chicago, Illinois, United States
8 University of Illinois Chicago, Chicago, Illinois, United States
9 University of Illinois Chicago, Chicago, Illinois, United States
10 University of Illinois Chicago, Chicago, Illinois, United States

Clonal hematopoiesis of indeterminate potential (CHIP) is an age-associated condition characterized by the expansion of hematopoietic stem cells (HSCs) carrying somatic mutations. CHIP is associated with an increased risk of hematologic malignancies and cardiovascular disease. Mutations such as TET2 and DNMT3A are well-established drivers of CHIP, yet, how the bone marrow niche regulates mutant HSC expansion and CHIP-associated cardiovascular complications remains unknown. Our previous studies showed that megakaryocytes are key components of the HSC niche and maintain HSC quiescence and lineage reconstitution potential through the secretion of platelet factor 4 (PF4). More recently, we showed that age-related alterations of the megakaryocytic niche and downregulation of PF4 levels are key drivers of HSC aging (Blood 2025). Here, we investigated whether disruption of the megakaryocyte-PF4 axis also contributes to TET2 CHIP progression and its cardiovascular manifestations.

As expected, young (2-3 months old) Tet2-mutant mice exhibited expansion of the HSC compartment compared with wild-type controls (1.7-fold increase, P = 0.0011). Notably, CHIP was accompanied by marked remodeling of the megakaryocytic niche, including reduced megakaryocyte size, decreased ploidy, and increased spatial distance between HSCs and megakaryocytes. These findings suggest that TET2 CHIP remodels the bone marrow by inducing an aging-like phenotype of the megakaryocytic niche. Nevertheless, healthy megakaryocytes retained the ability to suppress mutant HSC proliferation, suggesting that preservation of the megakaryocytic niche may restrain CHIP progression. To assess the contribution of megakaryocytes, we used PF4-Cre;iDTR mice to achieve long-term megakaryocyte depletion. Megakaryocyte ablation significantly accelerated TET2 CHIP progression, as evidenced by increased numbers of mutant HSCs (1.8-fold increase, P = 0.0045), myeloid-biased HSCs (2.4-fold increase, P = 0.0184), and granulocyte-monocyte progenitors (4.4-fold increase, P = 0.0021). Importantly, megakaryocyte depletion also exacerbated pathological cardiac remodeling, as indicated by increased heart-to-body weight ratio (1.6-fold increase, P = 0.0396) and cardiomyocyte hypertrophy, supporting a previously unrecognized role for the megakaryocytic niche in regulating the cardio-hematopoietic axis during CHIP.

Consistent with these findings, PF4 levels in the bone marrow extracellular fluid were significantly reduced in Tet2-mutant mice compared with controls (28.9% reduction, P = 0.0226). To directly evaluate the role of PF4 in CHIP progression, we employed a non-irradiated adoptive transfer model in which Tet2-deficient cells were transplanted into young PF4-deficient or wild-type recipient mice, preserving the native bone marrow microenvironment. Notably, CHIP progression was markedly accelerated in PF4-deficient recipients compared with controls. Conversely, continuous administration of recombinant PF4 (1 μg/day; 42 days) via osmotic pumps attenuated CHIP progression, as evidenced by a reduced contribution of mutant cells to the peripheral blood, compared with saline-treated controls. PF4 treatment additionally reduced systemic inflammation, reflected by lower circulating TNF-α (50% reduction, P = 0.0383) and IL-1β (58.7% reduction, P = 0.0505) levels.

In our recent study of HSC aging, we identified suppression of LDL uptake by myeloid-biased HSCs as a key mechanism through which PF4 preserves HSC function. We therefore investigated whether PF4 similarly regulates mutant HSCs. In agreement, Tet2-mutant HSCs exhibited the highest LDL uptake among all the hematopoietic populations examined in vitro, and PF4 treatment completely suppressed the elevated LDL uptake observed in mutant HSCs. These findings suggest that PF4 restrains Tet2-mutant HSC expansion, in part, by limiting LDL uptake and the metabolic programs that support HSC proliferation, myeloid-biased differentiation, and inflammatory activation.

Altogether, our findings identify premature megakaryocytic niche aging as a previously unrecognized mechanism driving CHIP progression and CHIP-associated pathological cardiac remodeling. More broadly, these studies establish the megakaryocyte-PF4 axis as a central regulator shared between physiological HSC aging and clonal hematopoiesis, and support restoration of this niche pathway as a potential therapeutic strategy to limit CHIP progression and its cardiovascular complications.

Sen Zhang, PhD: No relevant conflicts of interest to declare.